Skip to main content

Advertisement

SpringerLink
Log in

Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease

  • Cohort Studies
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Secukinumab is a monoclonal antibody directed against interleukin-17 approved for the treatment of psoriasis and spondyloarthritis. The favorable oncological profile of secukinumab in patients with a history of malignancy has been shown in patients with psoriasis. However, systematic data to this regard have not been published yet for patients with spondyloarthritis. The objective of the present study was to evaluate the oncological safety of secukinumab in patients affected by this group of diseases. We performed a retrospective study in which we identified from our cohort patients with spondyloarthritis treated with secukinumab and with a history of malignancy. These patients’ baseline demographic, treatment, rheumatological, and oncological data were collected. The neoplastic outcome (i.e., cancer recurrence or progression) after secukinumab start was then analyzed. Our study included 22 patients with spondyloarthritis. The most frequently reported oncological diagnosis was breast cancer (9 [41%] patients). Secukinumab was started after a median of 24 months following cancer diagnosis. At this time point, all but three patients were in oncological remission. No case of cancer relapse or progression was recorded over a median follow-up of 30 months. In the largest cohort reported to date to this regard, secukinumab was not associated with oncological recurrence or progression in patients with spondyloarthritis with a history of malignancy. Secukinumab may, therefore, represent a safe option in this clinical scenario.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Bass AR, Abdel-Wahab N, Reid PD, Sparks JA, Calabrese C, Jannat-Khah DP et al (2023) Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis 82(7):920–926

    Article  CAS  PubMed  Google Scholar 

  2. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316–326

    Article  CAS  PubMed  Google Scholar 

  3. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H (2009) IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway. J Exp Med 206(7):1457

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Zhao J, Chen X, Herjan T, Li X (2020) Cytokines focus: the role of interleukin-17 in tumor development and progression. J Exp Med 217(1):e20190297

    Article  PubMed  Google Scholar 

  5. Chen YS, Huang TH, Liu CL, Chen HS, Lee MH, Chen HW et al (2019) Locally targeting the IL-17/IL-17RA axis reduced tumor growth in a murine B16F10 melanoma model. Hum Gene Ther 30(3):273–285

    Article  CAS  PubMed  Google Scholar 

  6. Lebwohl M, Deodhar A, Griffiths CEM, Menter MA, Poddubnyy D, Bao W et al (2021) The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. Br J Dermatol 185(5):935–944

    Article  CAS  PubMed  Google Scholar 

  7. Li PH, Wai Chan SC, Lau CS, Yan Seto MT, Chung HY (2022) Conventional and biologic disease-modifying antirheumatic drugs are not associated with increase in or progression of cervical neoplasia among patients with spondyloarthritis. J Clin Rheumatol 28(1):E63–E68

    Article  PubMed  Google Scholar 

  8. Pellegrini C, Esposito M, Rossi E, Gisondi P, Piaserico S, Dapavo P et al (2022) Secukinumab in patients with psoriasis and a personal history of malignancy: a multicenter real-life observational study. Dermatol Ther (Heidelb). 12(11):2613

    Article  PubMed  PubMed Central  Google Scholar 

  9. Tekgoz E, Colak S, Yardimci KG, Kucuksahin O, Cinar M, Yilmaz S et al (2022) Physicians’ biological drug preference in patients with rheumatoid arthritis and spondyloarthritis with a history of malignancy: perspectives from the treasure database. J Clin Rheumatol 28(2):E318–E323

    Article  PubMed  Google Scholar 

  10. Monsour EP, Pothen J, Balaraman R. A Novel Approach to the Treatment of Pembrolizumab-induced Psoriasis Exacerbation: A Case Report. Cureus [Internet]. 2019 Oct 2 [cited 2023 Dec 2];11(10). Available from: https://pubmed.ncbi.nlm.nih.gov/31754559/

  11. Ma VT, Lao CD, Fecher LA, Schiopu E (2022) Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy. Immunotherapy 14(8):593–598

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Rudwaleit M, Van Der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777–783

    Article  CAS  PubMed  Google Scholar 

  13. Rudwaleit M, Van Der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70(1):25–31

    Article  CAS  PubMed  Google Scholar 

  14. Esfahani K, Miller WH (2017) Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med 376(20):1989–1991

    Article  PubMed  Google Scholar 

  15. Saura SP, Casimiro LM, Vázquez AG, Benavent MP, Guillén-Climent S, Villaescusa EM (2021) Successful outcome of psoriasis in a laryngeal cancer patient treated with ixekizumab, a possible beneficial treatment for both pathologies. Dermatol Online J. https://doi.org/10.5070/D327654071

    Article  Google Scholar 

  16. Vinaixa-Aranzazu A, Morillas-Lahuerta V, Blanco-De-Tord M, Carrascosa-Carrillo JM (2021) Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient. Eur J Dermatol 31(4):564–565

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Dong C (2008) IL-23/IL-17 biology and therapeutic considerations. J Immunotoxicol 5(1):43–46

    Article  PubMed  Google Scholar 

  18. Zhao J, Chen X, Herjan T, Li X (2020) The role of interleukin-17 in tumor development and progression. J Exp Med. https://doi.org/10.1084/jem.20190297

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

No funding was received for conducting this study.

Author information

Authors and Affiliations

  1. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy

    Nicola Farina, Alessandro Tomelleri, Nicola Boffini, Adriana Cariddi, Stefania Calvisi, Elena Baldissera, Marco Matucci-Cerinic & Lorenzo Dagna

  2. Vita-Salute San Raffaele University, Milan, Italy

    Alessandro Tomelleri, Marco Matucci-Cerinic & Lorenzo Dagna

Authors
  1. Nicola Farina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Tomelleri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicola Boffini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Adriana Cariddi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stefania Calvisi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elena Baldissera
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marco Matucci-Cerinic
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lorenzo Dagna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicola Farina.

Ethics declarations

Conflict of interest

AT, NB, EB, MMC, LD received consultation honoraria from Novartis.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Farina, N., Tomelleri, A., Boffini, N. et al. Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease. Rheumatol Int (2024). https://doi.org/10.1007/s00296-024-05571-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00296-024-05571-y

Keywords

Search

Navigation